Format

Send to

Choose Destination
Genet Med. 2018 Sep 12. doi: 10.1038/s41436-018-0258-3. [Epub ahead of print]

Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis.

Author information

1
Department of Clinical Nephroscience, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. hirokim@med.niigata-u.ac.jp.
2
Sanofi K.K., Sanofi Genzyme Medical Operations, Rare Disease Medical, Medical Science Liaison, Tokyo, Japan.
3
Department of Clinical Nephroscience, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
4
Department of Metabolism, Chiba Children's Hospital, Chiba, Japan.
5
Department of Pediatrics, Dokkyo Medical University Koshigaya Hospital, Koshigaya, Japan.
6
Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
7
Nishinomiya Watanabe Cardiovascular Center, Nishinomiya, Japan.
8
Department of Cardiology, Fujinomiya City General Hospital, Fujinomiya, Japan.
9
Department of Human Resource Development of Dialysis Therapy for Kidney Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan.
10
Sukoyaka Clinic, Gifu, Japan.
11
Department of Chronic Kidney Disease, Gifu University Graduate School of Medicine, Gifu, Japan.
12
Yamaguchi Prefectural Grand Medical Center, Hofu, Japan.
13
Department of Cardiovascular Medicine, Dokkyo Medical University, Mibu, Japan.
14
Department of Cardiology, Internal Medicine, Iwaki Kyoritsu General Hospital, Iwaki, Japan.
15
Department of Nephrology, Kashiwazaki General Hospital and Medical Center, Kashiwazaki, Japan.
16
Division of Neurology, Japanese Red Cross Asahikawa Hospital, Asahikawa, Japan.
17
Department of Nephrology, Tokyo Teishin Hospital, Tokyo, Japan.
18
Department of Cardiology, Japanese Red Cross Hamamatsu Hospital, Hamamatsu, Japan.
19
Division of Medical Genetics, Bioscience Medical Research Center, Niigata University Medical and Dental Hospital, Niigata, Japan.
20
Department of Cardiology, Tokyo Women's Medical University, Tokyo, Japan.
21
Division of Cardiology, Showa University Fujigaoka Hospital, Yokohama, Japan.
22
Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan.
23
Glyco Pharma Corporation, Oita, Japan.

Abstract

The PDF and HTML versions of the article have been updated to include the Creative Commons Attribution 4.0 International License information.

PMID:
30209272
DOI:
10.1038/s41436-018-0258-3

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center